CANRISK — Canadian Diabetes Risk Questionnaire
CANRISK (Public Health Agency of Canada) screens adults for prediabetes and undiagnosed type 2 diabetes from 15 questions. It was developed in adults aged 40–74; the Canadian Task Force uses ≥ 33 (high) and ≥ 43 (very high) to guide HbA1c screening.
Score interpretation
CANRISK 0–32 — about 1–17 % chance of type 2 diabetes over 10 years.
→ Canadian Task Force: no routine screening; lifestyle advice; reassess if risk factors change.
CANRISK 33–42 — about 33 % chance of type 2 diabetes over 10 years.
→ Screen with HbA1c every 3–5 years (Canadian Task Force); lifestyle programme; address cardiovascular risk factors.
CANRISK ≥ 43 — about 50 % chance of type 2 diabetes over 10 years.
→ Screen with HbA1c every year (Canadian Task Force); structured diabetes prevention programme; address cardiovascular risk factors.
Interpretation bands for the CANRISK. Apply clinical judgement and local guidance.
References
- Kaczorowski J, Robinson C, Nerenberg K. Development of the CANRISK questionnaire to screen for prediabetes and undiagnosed type 2 diabetes. Can J Diabetes 2009;33(4):381-385.
- Robinson CA, Agarwal G, Nerenberg K. Validating the CANRISK prognostic model for assessing diabetes risk in Canada's multi-ethnic population. Chronic Dis Inj Can 2011;32(1):19-31.
- Pottie K et al. Recommendations on screening for type 2 diabetes in adults. CMAJ 2012;184(15):1687-1696.
Related
Curated clinical cross-links plus same-class fallbacks.
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Botulinum Toxin Type A (ENT) · Neuromuscular Blocking Agent (Botulinum Toxin)
- Tuberculin purified protein derivative · Mycobacterial antigen for delayed-type hypersensitivity testing
- Ethosuximide · Antiepileptic — T-type Calcium Channel Blocker
- Botulinum toxin type A · Neuromuscular blocker (presynaptic)
- Metformin (Gestational Diabetes / PCOS) · Biguanide — Gestational Diabetes / PCOS
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.